Incb053914
MMR-deficient Tumors
Incyte CorporationPhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 23/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the MMR-deficient Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Parsaclisib Incyte Corporation | Phase 1 | CC |
Cyclophosphamide Incyte Corporation | Phase 1 | CC |
Pembrolizumab Incyte Corporation | Phase 1 | CC |
Epirubicin Incyte Corporation | Phase 1 | CC |
Itacitinib Incyte Corporation | Phase 1 | CC |
Same molecule, other indications
Incb053914 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →